Dyslipidemias D050171

Description

Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.   MeSH

Hierarchy View

Subtype Terms (3)

Hyperlipidemias
428 drugs (136 approved, 292 experimental)

Hypolipoproteinemias
12 drugs (6 approved, 6 experimental)

Smith-Lemli-Opitz Syndrome
6 drugs (3 approved, 3 experimental)


Phase 3 Indicated Drugs (134)

Key: D050171 (44) Subtype (90)

Phase 2 Indicated Drugs (117)

Key: D050171 (47) Subtype (70)

Other Experimental Indicated Drugs (133)

Key: D050171 (50) Subtype (83)


Organization Involved with Phase 4 Indications (239)

Key: D050171 (88) Subtype (151)

Aalborg University

Aarhus University

Abant Izzet Baysal University

Ajou University

All India Institute of Medical Sciences

Almond Board of California

American Heart Association

American Society of Health-System Pharmacists Research and Education Foundation

Astellas

Atlanta Research and Education Foundation

Bangabandhu Sheikh Mujib Medical University

Bar Ilan University

Baxalta

Bayer

B. Braun

Beijing Anzhen Hospital

Bio-Inova Life Sciences International

Birjand University of Medical Sciences

Boehringer Ingelheim

Bradford PCT

Cangzhou Center Hospital

Cantonal Hospital of St. Gallen

Cardinal Tien Hospital

Catholic University of Korea

Cedars-Sinai Medical Center

Central South University

Chang Gung University

Charles University

Chestnut Hill Temple Cardiology

China Academy of Chinese Medical Sciences

Chinese Academy of Medical Sciences

Chonbuk National University

Chong Kun Dang Pharmaceutical

Chonnam National University

Chungnam National University

CJ HealthCare Corp.

Columbia University

D16 Pharma & Biotec

Daewon Pharmaceutical Co., Ltd.

Daewoong Pharmaceutical Co. LTD.

Daiichi Sankyo

Department of Veteran Affairs

Dhaka Medical College

Dnipropetrovsk State Medical Academy

Dong-A Pharmaceutical

Dong-A University

Duke University

Eastern Virginia Medical School

Eli Lilly

Emory University

Enzymotec

Erasmus University Rotterdam

Essex Pharma

Eulji University

Federal University of Rio de Janeiro

Felizarta, Franco, M.D.

Foundation for Cardiovascular Research, Zurich

Foundation Research

Franco Felizarta, MD

Free University of Amsterdam

French National Agency for Research on AIDS and Viral Hepatitis

Fudan University

Fujian Provincial Hospital

Fundacio Lluita Contra la SIDA

Gachon University

Garvan Institute of Medical Research

Genovate Biotechnology Co., Ltd.,

Georgetown University

GlaxoSmithKline

Government of India

Government of Japan

Government of Mexico

Government of Russia

Guangdong Provincial Hospital of Traditional Chinese Medicine

Hallym University

Hanmi Pharmaceutical

Hanyang University

Harbin Medical University

Harvard University

Hebei University

Hellenic Atherosclerosis Society

Hospital Italiano de Buenos Aires

Hospital Santa Marcelina, Sao Paulo, Brasil

Hospital Universitari de Bellvitge

Hue University

Imperial College London

In His Image Family Medicine Residency

Inje University

Institute for Health Research IdiPAZ

Instituto Aragones de Ciencias de la Salud

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Japan Heart Foundation

JEWISH HOSPITAL

Jiao Tong University

Jinhua Central Hospital

Johns Hopkins University

Juntendo University

JW Pharmaceutical

Karolinska Institute

Keio University

Korea University

Kos Pharmaceuticals

Kuhnil Pharmaceutical Co., Ltd.

Kumamoto University

Kunming Medical University

Kyoto University

Kyung Hee University

Le Point Medical - Rond Point du Jour

Linical Co., Ltd.

Ludwig Maximilians University

Mahidol University

MDS Pharma

Medical University of Graz

Medical University of Vienna

Minerva SA

Mitsukoshi Health and Welfare

Na Homolce Hospital

Nang Kuang Pharmaceutical Co., Ltd.

Nanjing Medical University

National Center for Complementary and Integrative Health (NCCIH)

National Heart Foundation, Australia

National Heart, Lung, and Blood Institute (NHLBI)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Taiwan University

National University of Singapore

New England Research Institutes

New York University

Nicolaus Copernicus University

Ningxia Medical University

Nordic Pharma Group

Novartis

Nutrasource Diagnostics

Oregon Health and Science University

Osaka University

Ospedale di Circolo

Otsuka

Palacky University

Peking University

People's Liberation Army of China

Policlinico Casilino

Pontificia Universidad Catolica de Chile

Poznan University

Provident Clinical Research

Purdue University

Queen's University, Belfast

Radboud University

Radiant Research

Regeneron

Reliant Pharmaceuticals

Rio de Janeiro State University

Rovira i Virgili University

Rundo International Pharmaceutical Research & Development Co.,Ltd.

Sanford Health

Sanofi

Schering-Plough

Seoul National University

Servier

Shenzhen Baoan District People 's Hospital

Shionogi

Solvay

Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders

Stanford University

State University of New York, Buffalo

Sungkyunkwan University

Sun Yat-Sen University

Taichung Veterans General Hospital

Taipei Veteran General hospital

Takeda

Tel Aviv University

Tianjin Medical University

Tibotec

Tufts University

Tuscaloosa Research & Education Advancement Corporation (TREAC)

United States Army

Universidad Autonoma de Madrid

Université catholique de Louvain

University Hospital Brno

University of Amsterdam

University of Athens

University of Baghdad

University of Barcelona

University of Bologna

University of Caen-Normandie

University of California, Los Angeles

University of California, San Diego

University of California, San Francisco

University of Campania Luigi Vanvitelli

University of Campinas

University of Chile

University of Cincinnati

University of Colorado, Denver

University of Connecticut

University of Copenhagen

University of Florida

University of Freiburg

University of Ioannina

University of Kansas

University of Lausanne

University of Leipzig

University of Ljubljana

University of London

University of Manchester

University of Manitoba

University of Naples Frederico II

University of New South Wales

University of Oslo

University of Padova

University of Paris

University of Pennsylvania

University of Perugia

University of Pilsen

University of Pisa

University of Pittsburgh

University of Roma La Sapienza

University of Sassari

University of Southern Denmark

University of Ulsan

University of Utah

University of Vienna

University of Washington

University of Western Australia

University of Zaragoza

University of Zurich

Upsher-Smith Laboratories

Utrecht University

Virginia Commonwealth University

Vita-Salute University of Milano. Italy

Wakayama Medical University

Wenzhou Medical University

Westside Medical Associates of Los Angeles

Wuxi Third People 's Hospital

Yamaguchi University

Yerevan State Medical University, Armenia

Yeungnam University

Yiling Pharmaceutical Inc.

Yokohama City University

Yonsei University

Yuhan Pharmaceutical Company

Zhejiang University

Organization Involved with Phase 3 Indications (148)

Key: D050171 (41) Subtype (107)

Organization Involved with Phase 2 Indications (150)

Key: D050171 (46) Subtype (104)

Organization Involved with Other Experimental Indications (186)

Key: D050171 (53) Subtype (133)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.